<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="17867">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02874287</url>
  </required_header>
  <id_info>
    <org_study_id>XJTU1AF-CRS-2016-011</org_study_id>
    <nct_id>NCT02874287</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Hydroxychloroquine to Treat High-risk Coronary Artery Disease.</brief_title>
  <acronym>CHANGAN</acronym>
  <official_title>Hydroxychloroquine Assessment of Management Study in Coronary Artery Disease After Angiography.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital Xi'an Jiaotong University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether treated with hydroxychloroquine could
      improve therapeutic effect for patients with high-risk coronary artery disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This double blind, placebo, randomized controlled cross-over trial is going to assess if
      hydroxychloroquine could improve the high sensitivity C-reaction protein, blood lipid, blood
      glucose and blood pressure, also whether hydroxychloroquine could affect the secretion of
      inflammatory cytokines and the M1/M2 phenotype polarization of macrophages in patients with
      high-risk coronary artery disease.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of fasting high sensitivity C-reactive protein</measure>
    <time_frame>change from baseline at the 16th week, 39th week, 55th week.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change of blood pressure</measure>
    <time_frame>change from baseline at the 16th week, 39th week, 55th week.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of fasting blood lipid</measure>
    <time_frame>change from baseline at the 16th week, 39th week, 55th week.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of fasting blood glucose</measure>
    <time_frame>change from baseline at the 16th week, 39th week, 55th week.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of fasting insulin</measure>
    <time_frame>change from baseline at the 16th week, 39th week, 55th week.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of echocardiogram</measure>
    <time_frame>change from baseline at the 16th week, 39th week, 55th week.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of fasting Interleukin 6</measure>
    <time_frame>change from baseline at the 16th week, 39th week, 55th week.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of fasting tumor necrosis factor</measure>
    <time_frame>change from baseline at the 16th week, 39th week, 55th week.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Hydroxychloroquine first</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects are treated with hydroxychloroquine sulfate tablets first. After that, there is a washout period. And then subjects are treated with placebo tablets. All the subjects are treated with guideline-based secondary prevention of coronary heart disease medications.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo first</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects are treated with placebo tablets first. After that, there is a washout period. And then subjects are treated with hydroxychloroquine sulfate tablets. All the subjects are treated with guideline-based secondary prevention of coronary heart disease medications.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine Sulfate Tablets</intervention_name>
    <description>Subjects are treated with oral hydroxychloroquine sulfate tablets 200mg twice daily for 16 weeks. After that, there is a 23-week washout period. And then subjects are treated with oral placebo tablets 200mg twice daily for 16 weeks. All the interventions are built on the guideline-based secondary prevention of coronary heart disease medications.</description>
    <arm_group_label>Hydroxychloroquine first</arm_group_label>
    <other_name>Plaquenil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Tablets</intervention_name>
    <description>Subjects are treated with oral placebo tablets 200mg twice daily for 16 weeks. After that, there is a 23-week washout period. And then subjects are treated with oral hydroxychloroquine sulfate tablets 200mg twice daily for 16 weeks. All the interventions are built on the guideline-based secondary prevention of coronary heart disease medications.</description>
    <arm_group_label>placebo first</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients have the symptom of angina and ST-T change, as well as one coronary artery
             stenosis≥50% at least confirmed by coronary angiography or CT angiography at the age
             of 18-75 years old.

          -  High sensitivity C-reactive protein &gt;3mg/L, GRACE risk score≥90 .

          -  On guideline-based secondary prevention of coronary heart disease medications≥3
             months.

          -  No use of steroids, antibiotics, immunosuppressors a week before treatment.

        Exclusion Criteria:

          -  Retinal disease.

          -  Chronic hepatopathy.

          -  Renal dysfunction (creatinine&gt;175mmol/L).

          -  Moderately severe anemia, thrombocytopenia and leukocytopenia.

          -  Other contraindications for hydroxychloroquine.

          -  Active hemorrhage.

          -  Cancer or life expectancy&lt; a year.

          -  New York Heart Association (NYHA) functional class≥class III, Percutaneous Coronary
             Intervention or Coronary Artery Bypass Grafting in plan.

          -  Pregnancy and lactation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yue Wu, Professor</last_name>
    <role>Study Director</role>
    <affiliation>First Affiliated Hospital Xi'an Jiaotong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yue Wu, Professor</last_name>
    <phone>0086-029-8532-3664</phone>
    <email>imyuewu@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mengping Liu</last_name>
    <phone>18709241896</phone>
    <email>745365974@qq.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Rho YH, Oeser A, Chung CP, Milne GL, Stein CM. Drugs Used in the Treatment of Rheumatoid Arthritis: Relationship between Current Use and Cardiovascular Risk Factors. Arch Drug Inf. 2009 Jun;2(2):34-40.</citation>
    <PMID>19684849</PMID>
  </reference>
  <reference>
    <citation>Kim WU, Seo YI, Park SH, Lee WK, Lee SK, Paek SI, Cho CS, Song HH, Kim HY. Treatment with cyclosporin switching to hydroxychloroquine in patients with rheumatoid arthritis. Ann Rheum Dis. 2001 May;60(5):514-7.</citation>
    <PMID>11302876</PMID>
  </reference>
  <reference>
    <citation>Desai RJ, Eddings W, Liao KP, Solomon DH, Kim SC. Disease-modifying antirheumatic drug use and the risk of incident hyperlipidemia in patients with early rheumatoid arthritis: a retrospective cohort study. Arthritis Care Res (Hoboken). 2015 Apr;67(4):457-66. doi: 10.1002/acr.22483.</citation>
    <PMID>25302481</PMID>
  </reference>
  <reference>
    <citation>Achuthan S, Ahluwalia J, Shafiq N, Bhalla A, Pareek A, Chandurkar N, Malhotra S. Hydroxychloroquine's Efficacy as an Antiplatelet Agent Study in Healthy Volunteers: A Proof of Concept Study. J Cardiovasc Pharmacol Ther. 2015 Mar;20(2):174-80. doi: 10.1177/1074248414546324. Epub 2014 Aug 14.</citation>
    <PMID>25125385</PMID>
  </reference>
  <reference>
    <citation>Mercer E, Rekedal L, Garg R, Lu B, Massarotti EM, Solomon DH. Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals. Arthritis Res Ther. 2012 Jun 7;14(3):R135. doi: 10.1186/ar3868.</citation>
    <PMID>22676348</PMID>
  </reference>
  <reference>
    <citation>Capel RA, Herring N, Kalla M, Yavari A, Mirams GR, Douglas G, Bub G, Channon K, Paterson DJ, Terrar DA, Burton RA. Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current If: Novel electrophysiological insights and therapeutic potential. Heart Rhythm. 2015 Oct;12(10):2186-94. doi: 10.1016/j.hrthm.2015.05.027. Epub 2015 May 27.</citation>
    <PMID>26025323</PMID>
  </reference>
  <reference>
    <citation>Ben-Chetrit E, Fischel R, Hinz B, Levy M. The effects of colchicine and hydroxychloroquine on the cyclo-oxygenases COX-1 and COX-2. Rheumatol Int. 2005 Jun;25(5):332-5. Epub 2004 Feb 13.</citation>
    <PMID>14963695</PMID>
  </reference>
  <reference>
    <citation>Wasko MC, Hubert HB, Lingala VB, Elliott JR, Luggen ME, Fries JF, Ward MM. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA. 2007 Jul 11;298(2):187-93.</citation>
    <PMID>17622600</PMID>
  </reference>
  <reference>
    <citation>Solomon DH, Garg R, Lu B, Todd DJ, Mercer E, Norton T, Massarotti E. Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial. Arthritis Care Res (Hoboken). 2014 Aug;66(8):1246-51.</citation>
    <PMID>24470436</PMID>
  </reference>
  <reference>
    <citation>Gottenberg JE, Ravaud P, Puéchal X, Le Guern V, Sibilia J, Goeb V, Larroche C, Dubost JJ, Rist S, Saraux A, Devauchelle-Pensec V, Morel J, Hayem G, Hatron P, Perdriger A, Sene D, Zarnitsky C, Batouche D, Furlan V, Benessiano J, Perrodeau E, Seror R, Mariette X. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. JAMA. 2014 Jul 16;312(3):249-58. doi: 10.1001/jama.2014.7682.</citation>
    <PMID>25027140</PMID>
  </reference>
  <reference>
    <citation>Koch MW, Zabad R, Giuliani F, Hader W Jr, Lewkonia R, Metz L, Wee Yong V. Hydroxychloroquine reduces microglial activity and attenuates experimental autoimmune encephalomyelitis. J Neurol Sci. 2015 Nov 15;358(1-2):131-7. doi: 10.1016/j.jns.2015.08.1525. Epub 2015 Aug 28.</citation>
    <PMID>26344560</PMID>
  </reference>
  <reference>
    <citation>Hage MP, Al-Badri MR, Azar ST. A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role. Ther Adv Endocrinol Metab. 2014 Aug;5(4):77-85. doi: 10.1177/2042018814547204. Review.</citation>
    <PMID>25343023</PMID>
  </reference>
  <reference>
    <citation>Al-Bari MA. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother. 2015;70(6):1608-21. doi: 10.1093/jac/dkv018. Epub 2015 Feb 17. Review.</citation>
    <PMID>25693996</PMID>
  </reference>
  <reference>
    <citation>Detert J, Klaus P, Listing J, Höhne-Zimmer V, Braun T, Wassenberg S, Rau R, Buttgereit F, Burmester GR. Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands (OA TREAT): study protocol for a randomized controlled trial. Trials. 2014 Oct 27;15:412. doi: 10.1186/1745-6215-15-412.</citation>
    <PMID>25348033</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>August 16, 2016</lastchanged_date>
  <firstreceived_date>August 9, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Hydroxychloroquine</keyword>
  <keyword>Cross-Over Study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
